Last updated 9 August 2026 · Originally published 29 February 2020
Pain is the most common reason people buy CBD, and the evidence is more interesting than either its promoters or its critics tend to allow.
Cannabis-based medicines can help with some kinds of pain, particularly neuropathic pain. The average benefit in trials is usually modest, but it’s real — and for someone living with persistent pain, modest relief may still matter.
The important distinction is that most of the positive evidence comes from products containing meaningful amounts of THC. The evidence for CBD alone is smaller, less consistent, and only recently beginning to produce encouraging results.
What the biggest review found
The largest recent assessment of the question is an updated systematic review published in the Annals of Internal Medicine, which pooled 25 randomised placebo-controlled trials covering 2,303 patients, most with neuropathic pain.[1]
It sorted products by their THC-to-CBD ratio, which proved to be one of the clearest dividing lines — though formulation, dose and route matter too.
High-THC and balanced products produced small reductions in pain severity — real, but modest, and accompanied by moderate-to-large increases in dizziness, sedation and nausea.
Low THC-to-CBD products — the category closest to most retail CBD — have generally not produced better outcomes than placebo.
The review searched the literature to July 2025, so it doesn’t include the positive CBD trial published the following year.
The case for CBD specifically
The case for CBD specifically is worth setting out properly, because it isn’t nothing.
CBD has well-demonstrated anti-inflammatory activity in laboratory studies, and inflammation contributes to some painful conditions. It also acts on receptors directly involved in pain signalling — TRPV1 among them — and reduces pain behaviour in animals with induced arthritis.[9]
So there’s a coherent reason to expect CBD to help with at least some kinds of pain. This isn’t a case of a substance with no plausible mechanism being sold on hope.
The difficult step has been showing that those mechanisms translate into meaningful relief in people taking CBD alone — particularly at doses they can realistically buy.
The evidence is stronger for cannabis than for CBD
Many of the positive trials involve THC alongside CBD: nabiximols for neuropathic pain, cannabinoid medicines for multiple sclerosis symptoms, THC-containing preparations in other chronic pain conditions.
When a balanced THC–CBD medicine reduces pain, that shows the medicine works as a combination. It can’t establish that CBD would do the same alone — but nor should the result be discounted because THC contributed to it.
The practical conclusion is that cannabis-based medicines have a stronger case for pain than CBD does. Their average benefits are modest and side effects are more common, and they’re intoxicating in a way CBD isn’t. For people who haven’t found enough relief from standard treatment, that trade-off may still be worth it.
Where CBD alone has been tested
Until recently, the picture was largely negative.
A 2024 review gathered 16 randomised trials of verified or pharmaceutical-grade CBD across 12 pain conditions. Fifteen found no significant benefit over placebo.[2] The one positive result was small: 18 people with thumb arthritis reported improvements in pain and disability after two weeks of topical CBD.[3]
Several of the cleanest tests were negative. Oral CBD failed to beat placebo for acute low back pain in an emergency department trial,[4] and a randomised trial in hand osteoarthritis and psoriatic arthritis found no significant difference.[5] In an experimental study, even 800 mg didn’t alter healthy volunteers’ response to induced pain.[6] A 2026 trial in 200 people with fibromyalgia found 50 mg daily for 24 weeks did not outperform placebo — the result slightly favoured placebo, though the difference wasn’t considered clinically meaningful.[7]
We look at arthritis specifically in CBD and arthritis.
Then, in 2026, a positive result
The strongest CBD-only pain finding so far arrived in May 2026.
Researchers in Sydney randomised 40 people with chronic neuropathic pain after spinal cord injury, with 38 included in the main analysis. Each received CBD, rising to 800 mg daily, and placebo for six weeks apiece, in randomised order.[8]
Pain fell by around 14% on CBD against 6.5% on placebo. More tellingly, 37.8% of participants achieved at least a 30% reduction in pain during the CBD period, against 11.1% on placebo. Side effects were mostly mild — tiredness, nausea, diarrhoea.
That matters because neuropathic pain is genuinely difficult to treat and existing options are limited. It’s also one small trial, six weeks long, in one specific condition, at a dose that would be expensive and impractical to replicate with retail products.
But it changes the conclusion. It’s no longer accurate to say CBD has failed every persuasive test. It has failed in most conditions studied, while high-dose CBD may help some people with particular kinds of nerve pain.
What people report
Controlled trials aren’t the whole story. In surveys, many people who use CBD for chronic pain say it helps.
In one survey of 253 pain patients, 59% of those who had tried a CBD product said it reduced their pain, and around two-thirds said they had reduced other pain medication.[10] A survey of patients with spinal conditions found 46% of CBD users reported pain relief, while 24% reported no benefit.[11]
Those reports deserve to be taken seriously, but they can’t establish that CBD caused the improvement. The products weren’t standardised and some contained THC; people chose whether to use them; and expectation, other treatments and the natural course of pain could all be involved.
Still, the consistency of the reports is one reason CBD remains worth studying. Trials tell us what happens on average under controlled conditions. Consumer experience suggests there may be responders — or benefits involving sleep, mood and daily function — that conventional pain scores don’t always capture.
The International Association for the Study of Pain does not endorse the general use of cannabinoids for pain, citing insufficient high-quality evidence — though it acknowledges that some patients report benefit.
Worth reading alongside this: a pain physician’s account of how CBD looks from inside a clinic, which sits somewhere between the marketing and the trials.
The alternatives problem
There’s a habit in CBD-for-pain writing, including our own older articles, of starting with the side effects of conventional painkillers and then presenting CBD as the gentler option.
The concerns about opioids are legitimate. But “the alternative has problems” isn’t evidence that the substitute works, and for chronic pain the evidence-based options are broader than opioids: physiotherapy, graded exercise, cognitive behavioural approaches, certain antidepressants and anticonvulsants for neuropathic pain, and injections or procedures for specific conditions.
For someone who understands the uncertainty, CBD can be a reasonable addition to those options — particularly if existing treatments haven’t given enough relief. It shouldn’t be a reason to abandon treatments with stronger evidence.
If you’re going to try it
If you’re going to try it, a few things are worth knowing.
Decide what success would look like. Give it a consistent, time-limited trial and judge it by a meaningful change in pain, sleep or daily function. If nothing improves, escalating the dose is unlikely to be a good use of money — and high doses shouldn’t be attempted without medical oversight.
Topicals for something localised. If the pain has a specific site, a topical is the route designed for it. The evidence is thin, though one small trial in thumb arthritis was positive.[3]
Higher doses need medical oversight. The doses in the positive neuropathic pain trial were far above a retail serving, and at that level CBD can raise liver enzymes and interact more strongly with other medication. That’s manageable with monitoring — a reason to involve a doctor, not a reason to avoid it.
Check interactions. This matters more in pain than almost anywhere, because people with chronic pain often take several medications. CBD affects how the body processes many of them — see our guide to CBD and drug interactions.
Don’t stop prescribed treatment to make room for it, and tell your doctor you’re taking it.
Products vary enormously. A batch-specific lab report is the only way to know what you’re getting.
Where this leaves it
Cannabis-based medicines can help with some kinds of pain, particularly neuropathic pain. The reductions seen in trials are usually modest — but modest relief can still matter when pain has persisted despite everything else, and some people respond considerably better than the average suggests.
The evidence is stronger for THC-containing or balanced cannabis medicines than for CBD alone. That isn’t a weakness in the case for cannabis; it’s an important distinction between the plant and one isolated constituent.
CBD alone remains less established. Most controlled trials in arthritis, back pain, fibromyalgia and experimental pain have found no meaningful benefit. But the evidence is no longer uniformly negative: a small topical arthritis trial was positive, and the 2026 spinal cord injury trial is a credible signal that high-dose CBD may help some people with neuropathic pain.
That doesn’t make an ordinary low-dose CBD oil a proven painkiller. It means CBD is worth studying — not as a universal answer to pain, but as a possible treatment for particular conditions, or particular groups of responders.
If you want to try it, use a verified product, keep treatments with better evidence in place, and judge it by whether it produces a worthwhile improvement in your own pain or function. And if THC is medically and legally available to you, it’s worth knowing that cannabis-based medicines containing it currently have the stronger evidence base.
None of this is medical advice.
For more, see our guides to CBD and migraines, exercise recovery, and what the research actually shows, or browse Pain & Recovery.
References
- Chou R, Fu R, Ahmed AY, Morasco BJ. Cannabis-based products for chronic pain: an updated systematic review. Annals of Internal Medicine. 2026;179(2):230–241. doi:10.7326/ANNALS-25-03152
- Moore A, Straube S, Fisher E, Eccleston C. Cannabidiol (CBD) products for pain: ineffective, expensive, and with potential harms. The Journal of Pain. 2024;25(4):833–842. doi:10.1016/j.jpain.2023.10.009
- Heineman JT, Forster GL, Stephens KL, et al. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. Journal of Hand Surgery (American Volume). 2022;47(7):611–620. doi:10.1016/j.jhsa.2022.03.002
- Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Medical Journal of Australia. 2021;214(8):370–375. doi:10.5694/mja2.51014
- Vela J, Dreyer L, Petersen KK, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206–1214. doi:10.1097/j.pain.0000000000002466
- Schneider T, Zurbriggen L, Dieterle M, et al. Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia (CANAB I). Pain. 2022;163(1):e62–e71. doi:10.1097/j.pain.0000000000002310
- Rasmussen MU, Christensen R, Wæhrens EE, et al. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Annals of the Rheumatic Diseases. 2026;85(3):566–574. doi:10.1016/j.ard.2025.07.008
- Robertson RV, Suraev A, McCartney D, et al. High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. eClinicalMedicine. 2026;96:103986. doi:10.1016/j.eclinm.2026.103986
- Philpott HT, O’Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–2451. doi:10.1097/j.pain.0000000000001052
- Schilling JM, Hughes CG, Wallace MS, Sexton M, Backonja M, Moeller-Bertram T. Cannabidiol as a treatment for chronic pain: a survey of patients’ perspectives and attitudes. Journal of Pain Research. 2021;14:1241–1250. doi:10.2147/JPR.S278718
- Lovecchio F, McCarthy MH, Iyer S, et al. Prevalence of cannabidiol use in patients with spine complaints: results of an anonymous survey. International Journal of Spine Surgery. 2021.
About this article
Substantially rewritten in August 2026, consolidating our earlier reporting on CBD for pain, arthritis, back pain and nerve pain. This update adds the systematic reviews and trials published since, including the 2026 spinal cord injury trial, and sets out why most positive cannabis-and-pain evidence concerns THC-containing products rather than CBD alone. With earlier reporting by Colby McCoy and Lisa Rennie.
